PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30391994-5 2018 Here, we report that CD59, a phosphatidylinositol-anchored glycoprotein, is a candidate resistant gene for TAM therapies. Phosphatidylinositols 29-49 CD59 molecule (CD59 blood group) Homo sapiens 21-25 12898600-1 2003 CD59 (protectin), a phosphatidylinositol-anchored glycoprotein, is a member of the cell membrane-bound complement regulatory proteins that inhibits the formation of the terminal membrane attack complex (MAC) of complement. Phosphatidylinositols 20-40 CD59 molecule (CD59 blood group) Homo sapiens 0-4 28928834-5 2017 In addition, following treatment with 0.1 U/ml phosphatidylinositol-specific phospholipase C (PI-PLC) for 1 h, CD55 and CD59 surface expression was significantly decreased, and the cell lysis rate was further enhanced. Phosphatidylinositols 47-67 CD59 molecule (CD59 blood group) Homo sapiens 120-124 29541246-8 2018 The results also indicated that CD59 may transfer the palmitate group from phosphatidylinositol to LAT to form LAT palmitate, which then localizes to lipid rafts to regulate T-cell activation. Phosphatidylinositols 75-95 CD59 molecule (CD59 blood group) Homo sapiens 32-36 8759358-6 1996 Complement-mediated lysis in the presence of human complement was increased after partial removal of the m-RCA CD55 and CD59 with phosphatidylinositol-specific phospholipase C from the uveal melanoma cell line 92-1. Phosphatidylinositols 130-150 CD59 molecule (CD59 blood group) Homo sapiens 120-124 9834251-9 1998 Pretreatment of microvesicles, RBC eluate preparations, and HDL with phosphatidylinositol-specific, phospholipase C, abrogated protein transfer to deficient cells, indicating that increased cell-associated CD55 and CD59 levels were related to insertion of the intact GPI moiety, rather than to simple adhesion. Phosphatidylinositols 69-89 CD59 molecule (CD59 blood group) Homo sapiens 215-219 9204953-3 1997 Removal of the lipid-linked complement regulatory proteins CD59 and decay-accelerating factor (DAF) by treatment of the cells with phosphatidylinositol-specific phospholipase C (PIPLC) resulted in increased C3b and C5b-9 deposition on the cells and a slight increase in cell death. Phosphatidylinositols 131-151 CD59 molecule (CD59 blood group) Homo sapiens 59-63 9185710-8 1997 Treatment of DU 145 and PC3 cells with phosphatidylinositol-specific phospholipase C caused a significant decrease of CD59 expression indicating that the CD59 expressed by prostate cancer cells is anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) linkage. Phosphatidylinositols 39-59 CD59 molecule (CD59 blood group) Homo sapiens 118-122 9185710-8 1997 Treatment of DU 145 and PC3 cells with phosphatidylinositol-specific phospholipase C caused a significant decrease of CD59 expression indicating that the CD59 expressed by prostate cancer cells is anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) linkage. Phosphatidylinositols 39-59 CD59 molecule (CD59 blood group) Homo sapiens 154-158 7594597-7 1995 Treatment of virus with phosphatidylinositol-specific phospholipase C (PI-PLC), which removes glycosylphosphatidylinositol-anchored CD55 and CD59, increased the sensitivity of HTLV-I to C-mediated destruction in the presence of anti-HTLV-I Abs. Phosphatidylinositols 24-44 CD59 molecule (CD59 blood group) Homo sapiens 141-145 8954321-4 1996 Phosphatidyl inositol-phospholipase C treatment diminished or abolished cell surface expression of DAF and HRF20 on BAEC. Phosphatidylinositols 0-21 CD59 molecule (CD59 blood group) Homo sapiens 107-112 7553895-5 1995 Treatment with phosphatidylinositol-specific phospholipase C released both the CD55 and CD59 antigens from the surface of CD56+CD3- cells, indicating that both are GPI-anchored, as they are on other lymphocytes. Phosphatidylinositols 15-35 CD59 molecule (CD59 blood group) Homo sapiens 88-92 7522635-3 1994 Specifically, somatic mutations in the phosphatidylinositol glycan class A gene result in the ability of blood cells to anchor complement-regulatory proteins (CD59 and DAF) to the cell surface via glycosyl phosphatidylinositol (GPI). Phosphatidylinositols 39-59 CD59 molecule (CD59 blood group) Homo sapiens 159-163 7538980-4 1995 Treatment of melanoma cells with 5U/ml of phosphatidylinositol-specific phospholipase C completely abolished cell-surface expression of CD59. Phosphatidylinositols 42-62 CD59 molecule (CD59 blood group) Homo sapiens 136-140 7543140-10 1995 Phosphatidylinositol-specific phospholipase C treatment of either cell line-derived or primary isolates of HIV-1 increased sensitivity to complement while incubation of sensitive virus with purified CD55 and CD59 increased resistance to complement. Phosphatidylinositols 0-20 CD59 molecule (CD59 blood group) Homo sapiens 208-212 7527603-3 1994 Human DAF and CD59 were released from the surface of transfected rat cells by phosphatidylinositol phospholipase C, demonstrating that the two molecules were linked to the cell membrane by means of a glycolipid anchor. Phosphatidylinositols 78-98 CD59 molecule (CD59 blood group) Homo sapiens 14-18 7915914-2 1994 The enzyme incorporated [3H]inositol into phosphoinositides at a maximal rate of 419 pmol min-1 mg protein-1. Phosphatidylinositols 42-59 CD59 molecule (CD59 blood group) Homo sapiens 90-95 7522216-7 1994 Evidence for a mobilizable intracellular pool of CD59 was obtained by detection of increased binding of 1F5 following PMN permeabilization; CD59 could also be re-expressed after stripping by phosphatidylinositol specific phospholipase C (PI-PLC) by treatment with FMLP or A23187. Phosphatidylinositols 191-211 CD59 molecule (CD59 blood group) Homo sapiens 49-53 7522216-7 1994 Evidence for a mobilizable intracellular pool of CD59 was obtained by detection of increased binding of 1F5 following PMN permeabilization; CD59 could also be re-expressed after stripping by phosphatidylinositol specific phospholipase C (PI-PLC) by treatment with FMLP or A23187. Phosphatidylinositols 191-211 CD59 molecule (CD59 blood group) Homo sapiens 140-144 7915914-3 1994 In the absence of CMP, the labelling rate due to the PtdIns headgroup exchanging enzyme was 36 pmol min-1 mg protein-1. Phosphatidylinositols 53-59 CD59 molecule (CD59 blood group) Homo sapiens 100-105 7692919-2 1993 CD59, a phosphatidyl-inositol-anchored glycoprotein, inhibits the formation of the terminal membrane attack complex (MAC) of complement and was found to be a second ligand for CD2 contributing to T-cell activation. Phosphatidylinositols 8-29 CD59 molecule (CD59 blood group) Homo sapiens 0-4 8139153-5 1994 Phosphatidyl-inositol (PI)-phospholipase C (PLC) reduced MACIF expression in these cells, suggesting that MACIF is a PI-linked membrane protein in GECs. Phosphatidylinositols 0-21 CD59 molecule (CD59 blood group) Homo sapiens 57-62 8139153-5 1994 Phosphatidyl-inositol (PI)-phospholipase C (PLC) reduced MACIF expression in these cells, suggesting that MACIF is a PI-linked membrane protein in GECs. Phosphatidylinositols 0-21 CD59 molecule (CD59 blood group) Homo sapiens 106-111 7689003-1 1993 CD59 (leukocyte cluster of differentiation antigen 59), is a phosphatidylinositol glycan-anchored membrane protein that inhibits lysis of cells by terminal complement system components. Phosphatidylinositols 61-81 CD59 molecule (CD59 blood group) Homo sapiens 0-4 7683151-4 1993 Digestion analyses with phosphatidylinositol-specific phospholipase C, an enzyme that releases GPI-anchored proteins from cell surfaces, showed that DAF and CD59 molecules with GPI anchors containing unacylated inositol were preferentially lost. Phosphatidylinositols 24-44 CD59 molecule (CD59 blood group) Homo sapiens 157-161 7689003-1 1993 CD59 (leukocyte cluster of differentiation antigen 59), is a phosphatidylinositol glycan-anchored membrane protein that inhibits lysis of cells by terminal complement system components. Phosphatidylinositols 61-81 CD59 molecule (CD59 blood group) Homo sapiens 16-53 1689219-4 1990 CD59 is a widely distributed 18,000-25,000 Mr protein anchored to the cell membrane by phosphatidylinositol (PI). Phosphatidylinositols 87-107 CD59 molecule (CD59 blood group) Homo sapiens 0-4 2242615-9 1990 These results indicate that HRF20 attaches to keratinocytes and blood vessels via phosphatidylinositol, regulating the formation of membrane attack complexes of homologous complement on the cell membrane. Phosphatidylinositols 82-102 CD59 molecule (CD59 blood group) Homo sapiens 28-33 1698362-1 1990 HRF20, a 20 kDa homologous restriction factor, is a membrane glycoprotein anchored via galactosyl phosphatidyl inositol. Phosphatidylinositols 98-119 CD59 molecule (CD59 blood group) Homo sapiens 0-5 1698362-1 1990 HRF20, a 20 kDa homologous restriction factor, is a membrane glycoprotein anchored via galactosyl phosphatidyl inositol. Phosphatidylinositols 98-119 CD59 molecule (CD59 blood group) Homo sapiens 9-45 1372260-6 1992 CD59 was released from the surface of HUVEC by phosphatidylinositol-specific phospholipase C, demonstrating that it is attached to the cell membrane by means of a glycolipid anchor. Phosphatidylinositols 47-67 CD59 molecule (CD59 blood group) Homo sapiens 0-4 1710238-1 1991 The CD59 Ag is a 20-kDa protein that is widely expressed on most leukocytes and RBC, is coupled to the membrane by a phosphatidylinositol-glycan anchoring structure, plays a role in cell interaction between monocytes and T cells, and also functions as an inhibitor of cytolysis by the terminal C components C5b-9. Phosphatidylinositols 117-137 CD59 molecule (CD59 blood group) Homo sapiens 4-8 1690178-2 1990 HRF20 has been identified by a monoclonal antibody (mAb), 1F5, and is one of the phosphatidylinositol(PI)-anchored cell-surface glycoproteins. Phosphatidylinositols 81-101 CD59 molecule (CD59 blood group) Homo sapiens 0-5 1689670-0 1990 Analysis of PI (phosphatidylinositol)-anchoring antigens in a patient of paroxysmal nocturnal hemoglobinuria (PNH) reveals deficiency of 1F5 antigen (CD59), a new complement-regulatory factor. Phosphatidylinositols 16-36 CD59 molecule (CD59 blood group) Homo sapiens 137-148 1689670-0 1990 Analysis of PI (phosphatidylinositol)-anchoring antigens in a patient of paroxysmal nocturnal hemoglobinuria (PNH) reveals deficiency of 1F5 antigen (CD59), a new complement-regulatory factor. Phosphatidylinositols 16-36 CD59 molecule (CD59 blood group) Homo sapiens 150-154 2475570-7 1989 CD59 antigen was released from the surface of transfected COS cells by phosphatidylinositol-specific phospholipase C, demonstrating that it is attached to the cell membrane by means of a glycolipid anchor; it is therefore likely to be absent from the surface of affected erythrocytes in the disease paroxysmal nocturnal hemoglobinuria. Phosphatidylinositols 71-91 CD59 molecule (CD59 blood group) Homo sapiens 0-4 2876780-2 1986 Two of the three bands that are precipitated from metabolically labeled cells are expressed on the cell surface and can be recovered from the supernatants of cells treated with a phosphatidylinositol-specific phospholipase C. Thus TAP appears to be attached to the cell membrane via this lipid. Phosphatidylinositols 179-199 CD59 molecule (CD59 blood group) Homo sapiens 231-234 2918859-0 1989 Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol. Phosphatidylinositols 108-128 CD59 molecule (CD59 blood group) Homo sapiens 72-78